MYHEP 400MG 28 TABLETS

INDICATIONS AND USAGE: IT IS A HEPATITIS C VIRUS (HCV) NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITOR INDICATED FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN. *EFFICACY HAS BEEN ESTABLISHED IN SUBJECTS WITH HCV GENOTYPE 1 2 3 OR 4 INFECTION INCLUDING THOSE WITH HEPATOCELLULAR CARCINOMA MEETING MILAN CRITERIA (AWAITING LIVER TRANSPLANTATION) AND THOSE WITH HCV/HIV-1 CO-INFECTION. *DOSAGE AND ADMINISTRATION: * ONE 400 MG TABLET TAKEN ONCE DAILY WITH OR WITHOUT FOOD. * SHOULD BE USED IN COMBINATION WITH RIBAVIRIN OR IN COMBINATION WITH PEGYLATED INTERFERON AND RIBAVIRIN FOR THE TREATMENT OF CHC. RECOMMENDED COMBINATION THERAPY: HCV MONO-INFECTED AND HCV/HIV-1 CO-INFECTED TREATMENT DURATION GENOTYPE 1 OR 4 SOVALDI + PEG-INTERFERON ALFA + RIBAVIRIN 12 WEEKS GENOTYPE 2 SO